NCT06896994 Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
| NCT ID | NCT06896994 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Postherpetic Neuralgia |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-04-01 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).
Eligibility Criteria
Inclusion Criteria: 1. Ages more than 18 years; 2. Pain present for more than 3 months after healing of a herpes zoster skin rash; 3. Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)； 4. Failed to respond to or tolerate the effective dose of pregabalin monotherapy. Exclusion Criteria: 1. Obstructive sleep apnoea syndrome; 2. Those who receive interventional treatments; 3. A history of systemic immune diseases, organ transplantation, or cancers; 4. A history of severe cardiopulmonary, hepatic or renal dysfunction; 5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium; 6. Currently using monoamine oxidase inhibitors (MAOIs); 7. Having untreated angle-closure glaucoma; 8. Those suffering from increased intracranial pressure； 9. Comorbid hyperthyroidism or phaeochromocytoma; 10. Suspected or confirmed history of drug abuse; 11. Having contraindications to esketamine, pregabaline or duloxetine; 12. Communication difficulties; 13. Women who are preparing for pregnancy, in the pregnancy or lactation period.
Contact & Investigator
Fang Luo, M.D.
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT06896994 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Postherpetic Neuralgia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06896994 currently recruiting?
Yes, NCT06896994 is actively recruiting participants. Contact the research team at 13611326978@163.com for enrollment information.
Where is the NCT06896994 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06896994 clinical trial?
NCT06896994 is sponsored by Beijing Tiantan Hospital. The principal investigator is Fang Luo, M.D. at Beijing Tiantan Hospital. The trial plans to enroll 150 participants.